Ocumension Therapeutics
HKEX:1477

Watchlist Manager
Ocumension Therapeutics Logo
Ocumension Therapeutics
HKEX:1477
Watchlist
Price: 4.41 HKD 0.46%
Market Cap: 3.6B HKD
Have any thoughts about
Ocumension Therapeutics?
Write Note

Ocumension Therapeutics
Operating Expenses

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Ocumension Therapeutics
Operating Expenses Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Expenses CAGR 3Y CAGR 5Y CAGR 10Y
Ocumension Therapeutics
HKEX:1477
Operating Expenses
-ÂĄ549.9m
CAGR 3-Years
37%
CAGR 5-Years
-21%
CAGR 10-Years
N/A
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Operating Expenses
-ÂĄ6.4B
CAGR 3-Years
-8%
CAGR 5-Years
-6%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Operating Expenses
-ÂĄ1.3B
CAGR 3-Years
-6%
CAGR 5-Years
-7%
CAGR 10-Years
-16%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Operating Expenses
-ÂĄ16.2B
CAGR 3-Years
4%
CAGR 5-Years
-3%
CAGR 10-Years
-15%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Operating Expenses
-ÂĄ6.5B
CAGR 3-Years
-3%
CAGR 5-Years
-2%
CAGR 10-Years
-14%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Operating Expenses
-ÂĄ1.1B
CAGR 3-Years
-12%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Ocumension Therapeutics
Glance View

Market Cap
3.6B HKD
Industry
Pharmaceuticals

Ocumension Therapeutics engages in the identification, development, and commercialization of ophthalmic therapies. The company is headquartered in Suzhou, Jiangsu. The company went IPO on 2020-07-10. Its main products include OT-401 (YUTIQ), OT-1001 (ZERVIATE), OT-502 (DEXYCU), OT-301 (NCX 470), OT-101 and OT-202, among others. The firm conducts its businesses in the domestic market.

Intrinsic Value
5.8 HKD
Undervaluation 24%
Intrinsic Value
Price

See Also

What is Ocumension Therapeutics's Operating Expenses?
Operating Expenses
-549.9m CNY

Based on the financial report for Dec 31, 2023, Ocumension Therapeutics's Operating Expenses amounts to -549.9m CNY.

What is Ocumension Therapeutics's Operating Expenses growth rate?
Operating Expenses CAGR 5Y
-21%

Over the last year, the Operating Expenses growth was 0%. The average annual Operating Expenses growth rates for Ocumension Therapeutics have been 37% over the past three years , -21% over the past five years .

Back to Top